NIH R01 · 2024
Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL
Background. Despite the significant success of recent therapies, Acute Lymphoblastic Leukemia (ALL) remains the second leading cause of childhood death. The discordance between therapeutic improvements and poor outcomes is partially caused by the difficulty of salvaging relapsed disease. While outcomes have improved in de novo treatment, dismal rates of overall survival (less than 25%) were observed in relapsed subtypes of ALL. The clinical armamentarium for treating relapsed or refractory T-ALL must be supported with new options. Strategy. While most of T-ALL cases exhibit gain-of-function mutations in Notch signaling, therapies against Notch have not fulfilled their clinical promise. To…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.